What is PhysioRx?
PhysioRx operates as an FDA-regulated and AHCA-certified tissue bank, specializing in the procurement and distribution of high-quality conventional tissue and innovative surgical technologies. The company has strategically diversified its portfolio to include cellular placental tissue allografts, catering to the complex needs of modern surgical environments. By maintaining rigorous compliance standards and fostering deep expertise in biological materials, PhysioRx serves as a vital link in the medical supply chain, ensuring that healthcare providers have access to the specialized components necessary for complex reconstructive and regenerative procedures.
How much funding has PhysioRx raised?
PhysioRx has raised a total of $35K across 1 funding round:
Debt
$35K
Debt (2021): $35K with participation from PPP
Key Investors in PhysioRx
PPP
Public-Private Partnership
What's next for PhysioRx?
With the recent infusion of capital, PhysioRx is poised to transition into a phase of aggressive market scaling and technological integration. The strategic focus will likely center on expanding its DME lines and enhancing its logistical capabilities to meet the rising demand for advanced allograft solutions. As the company navigates the complexities of the Series B/C stage, management will prioritize operational efficiency and the continued development of its proprietary tissue processing methodologies. This growth phase is expected to solidify the company's competitive advantage, potentially paving the way for further market penetration and long-term sustainability in the regenerative medicine landscape.
See full PhysioRx company page
